NCT03509922View on ClinicalTrials.gov

A Study to Evaluate the Effect of Sarpogrelate on Blood Hyperviscosity

PHASE4CompletedINTERVENTIONAL
Enrollment

60

Participants

Timeline

Start Date

October 11, 2018

Primary Completion Date

December 26, 2019

Study Completion Date

March 5, 2020

Conditions
Peripheral Artery Disease, PAD
Interventions
DRUG

Anplag Tab. 100mg bid

sarpogrelate hydrochloride 100mg bid for 24 weeks

DRUG

Anplag Tab. 100mg tid

sarpogrelate hydrochloride 100mg tid for 24 weeks

Trial Locations (1)

Unknown

The Catholic University of Korea, Uijeongbu ST. Mary's Hospital, Uijeongbu-si

All Listed Sponsors
lead

Yuhan Corporation

INDUSTRY

NCT03509922 - A Study to Evaluate the Effect of Sarpogrelate on Blood Hyperviscosity | Biotech Hunter | Biotech Hunter